8 Knots Management LLC Sells 659,963 Shares of CVS Health Corporation $CVS

Key Points

• 8 Knots Management LLC cut its CVS Health stake by 56.2% in the fourth quarter, selling 659,963 shares and leaving it with 514,834 shares worth about $40.9 million.
• CVS Health reported stronger-than-expected Q1 results, posting EPS of $2.57 versus the $2.21 estimate and revenue of $100.43 billion, while also guiding FY 2026 EPS to $7.30-$7.50.
• Analyst sentiment remains upbeat, with several firms raising price targets and the stock receiving a consensus rating of “Moderate Buy” with a target price of $100.68.

8 Knots Management LLC lessened its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 56.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 514,834 shares of the pharmacy operator's stock after selling 659,963 shares during the period. CVS Health accounts for 4.7% of 8 Knots Management LLC's holdings, making the stock its 6th biggest holding. 8 Knots Management LLC's holdings in CVS Health were worth $40,857,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Adams Diversified Equity Fund Inc. lifted its holdings in CVS Health by 175.5% in the fourth quarter. Adams Diversified Equity Fund Inc. now owns 351,300 shares of the pharmacy operator's stock valued at $27,879,000 after buying an additional 223,800 shares during the period. Atlas Capital Advisors Inc. acquired a new position in CVS Health in the fourth quarter valued at $2,955,000. Aptus Capital Advisors LLC lifted its holdings in CVS Health by 1.7% in the fourth quarter. Aptus Capital Advisors LLC now owns 15,060 shares of the pharmacy operator's stock valued at $1,195,000 after buying an additional 246 shares during the period. CreativeOne Wealth LLC raised its holdings in shares of CVS Health by 25.7% during the fourth quarter. CreativeOne Wealth LLC now owns 8,592 shares of the pharmacy operator's stock valued at $682,000 after purchasing an additional 1,754 shares during the period. Finally, Transamerica Financial Advisors LLC raised its holdings in shares of CVS Health by 113.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 894 shares of the pharmacy operator's stock valued at $71,000 after purchasing an additional 476 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Stock Performance

NYSE CVS opened at $101.87 on Friday. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $102.77. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a market capitalization of $129.98 billion, a PE ratio of 44.88, a P/E/G ratio of 1.00 and a beta of 0.62. The company's 50 day simple moving average is $86.91 and its two-hundred day simple moving average is $80.78.

CVS Health (NYSE:CVS - Get Free Report) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion for the quarter, compared to analysts' expectations of $94.99 billion. During the same period in the prior year, the company posted $2.25 EPS. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.6%. CVS Health's dividend payout ratio is presently 117.18%.

Insiders Place Their Bets

In other news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares of the company's stock, valued at $586,842,501.45. This represents a 24.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last three months. Insiders own 0.85% of the company's stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding access to GLP-1 weight-loss drugs, including bringing back Zepbound and loosening restrictions on newer oral therapies, which could improve customer engagement and prescription volume while supporting its broader healthcare platform. Is CVS (CVS) Using GLP-1 Access and AI Tools to Redefine Its Healthcare Moat?
• Positive Sentiment: The company is also pushing AI deeper into pharmacy, insurance, and care delivery operations, aiming to cut administrative burden, improve efficiency, and potentially widen margins over time. Healthy Returns: CVS Health executives on reducing health care's biggest pain points
• Positive Sentiment: CVS Health has launched Aetna Mental Health on Demand, which gives members faster access to care and shows the company is trying to strengthen service offerings across its insurance business. 5 Low Price-to-Book Stocks That Are Worth Buying in June
• Positive Sentiment: Recent coverage notes CVS at a 52-week high and highlights strong post-earnings momentum, while screening screens and “trending stock” mentions suggest investor interest remains elevated. CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?
• Neutral Sentiment: CVS is also working with Fluency to move autonomous AI agents from pilot projects into production, but the financial impact is still early and not yet quantified. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Neutral Sentiment: News that Mass General Brigham and CVS are moving closer to a primary care partnership and that the stock is being heavily discussed by retail investors adds attention, but these items are not immediate earnings drivers. Mass General Brigham and CVS primary care partnership moves closer to reality
• Negative Sentiment: Musab Balbale’s departure adds some leadership turnover, though the market may view it as a limited issue unless more executive changes follow. Musab Balbale Departs CVS Health

Wall Street Analyst Weigh In

CVS has been the topic of several research reports. Royal Bank Of Canada upped their price objective on shares of CVS Health from $93.00 to $107.00 and gave the company an "outperform" rating in a report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of CVS Health from $88.00 to $92.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Leerink Partners reaffirmed an "outperform" rating and issued a $98.00 price objective on shares of CVS Health in a research report on Thursday, March 5th. Truist Financial upped their price objective on shares of CVS Health from $102.00 to $108.00 and gave the stock a "buy" rating in a research report on Monday, June 1st. Finally, UBS Group boosted their target price on shares of CVS Health from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Monday, June 8th. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $100.68.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.